NatHER: protocol for systematic evaluation of trends in survival among patients with HER2-positive advanced breast cancer

BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) is an aggressive form of breast cancer and is historically associated with poor outcomes compared with HER2-negative MBC. Since 1998, four drugs have been globally approved for the targeted treatment...

Full description

Saved in:
Bibliographic Details
Published in:Syst Rev
Main Authors: Korner, Eli J., Morris, Anne, Allen, Isabel Elaine, Hurvitz, Sara, Beattie, Mary S., Kalesan, Bindu
Format: Artigo
Language:Inglês
Published: BioMed Central 2015
Subjects:
Protocol
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4591587/
https://ncbi.nlm.nih.gov/pubmed/26428301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13643-015-0118-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items